Organigram Holdings Inc. OGI shares lost 63.58% over the past 12 months. Cantor Fitzgerald lowered its price target Monday for the cannabis company ahead of its first-quarter report on Jan. 27.
- Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
- Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
- Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.
The Organigram Analyst
Pablo Zuanic maintained an Overweight rating on Organigram and cut the price target from CA$13.30 ($10.25) to CA$9.50 ($7.32).
The Organigram Thesis
In order to mirror market share that's more in line with the August quarter than prior quarters, Cantor trimmed its sales estimates for Organigram, Zuanic said in a Monday note. (See his track record here.)
The January and May quarters were not a true representation of the underlying movements considering the effects of price discounts and returns, the analyst said.
The consensus estimates are high, Zuanic said, adding that Cantor is 5% below the Street on sales — and 40% below the conensus adjusted gross margin estimate.
"That said, OGI remains one of the most cost-efficient operators in Canada, with a focused approach, and we continue to think the valuation is attractive (3x 1yF EV/Sales compared with most direct peers at 7-8x)."
It will take a while for Organigram to regain credibility after the company's August quarter, the analyst said.
Organigram experienced a significant drop to $16 million in net sales in the August quarter versus net sales of $25-27 million in the second and third quarters, he said, adding that “we expect minor improvements to $18Mn in the Nov Qtr.”
Organigram Price Action
Organigram shares were down 3.52% at $2.19 at the time of publication.
Related Links:
Aurora Cannabis Analyst Lowers Price Target, Says Company Needs 'Greater Financial Discipline'
Organigram Receives Health Canada Licenses For Chocolate Production
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!